Enterprise Value (EV): $49.96B
The enterprise value (EV) is $49.96B as of Sunday, June 28, 2026.
EW Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$49.96B
EW Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | $49.96B |
| Cencora, Inc. (COR)vs › | $55.67B | $65.82B |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | $60.70B |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | $72.96B |
| Humana Inc. (HUM)vs › | $46.08B | $55.13B |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | $44.41B |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | $64.95B |
| Boston Scientific Corporation (BSX)vs › | $65.74B | $75.25B |
| Agilent Technologies, Inc. (A)vs › | $38.41B | $39.96B |
| Medline Inc. (MDLN)vs › | $32.87B | $43.27B |
Enterprise Value Calculation
Market Cap
$52.27B
Total Debt
$622.80M
Cash
$2.94B
Enterprise Value
$49.96B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Edwards Lifesciences Corporation (EW)?
- The enterprise value (EV) for EW stock is $49.96B.
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian